The ENL YEATS epigenetic reader domain critically links MLL-ENL to leukemic stem cell frequency in t(11;19) Leukemia
- 26 November 2022
- journal article
- research article
- Published by Springer Nature in Leukemia
- Vol. 37 (1) , 190-201
Abstract
MLL (KMT2a) translocations are found in ~10% of acute leukemia patients, giving rise to oncogenic MLL-fusion proteins. A common MLL translocation partner is ENL and associated with a poor prognosis in t(11;19) patients. ENL contains a highly conserved N-terminal YEATS domain that binds acetylated histones and interacts with the PAF1c, an epigenetic regulator protein complex essential for MLL-fusion leukemogenesis. Recently, wild-type ENL, and specifically the YEATS domain, was shown to be essential for leukemic cell growth. However, the inclusion and importance of the YEATS domain in MLL-ENL-mediated leukemogenesis remains unexplored. We found the YEATS domain is retained in 84.1% of MLL-ENL patients and crucial for MLL-ENL-mediated leukemogenesis in mouse models. Mechanistically, deletion of the YEATS domain impaired MLL-ENL fusion protein binding and decreased expression of pro-leukemic genes like Eya1 and Meis1. Point mutations that disrupt YEATS domain binding to acetylated histones decreased stem cell frequency and increased MLL-ENL-mediated leukemia latency. Therapeutically, YEATS containing MLL-ENL leukemic cells display increased sensitivity to the YEATS inhibitor SGC-iMLLT compared to control AML cells. Our results demonstrate that the YEATS domain is important for MLL-ENL fusion protein-mediated leukemogenesis and exposes an “Achilles heel” that may be therapeutically targeted for treating t(11;19) patients.Keywords
Funding Information
- U-M | MCubed, University of Michigan
- Michigan Drug Discovery
- U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01-HL-136420)
- U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30CA046592)
This publication has 56 references indexed in Scilit:
- Leukemia Fusion Target AF9 Is an Intrinsically Disordered Transcriptional Regulator that Recruits Multiple Partners via Coupled Folding and BindingStructure, 2013
- RUNX1 Is a Key Target in t(4;11) Leukemias that Contributes to Gene Activation through an AF4-MLL Complex InteractionCell Reports, 2013
- Human Polymerase-Associated Factor complex (PAFc) connects the Super Elongation Complex (SEC) to RNA polymerase II on chromatinProceedings of the National Academy of Sciences, 2011
- MLL-Rearranged Leukemia Is Dependent on Aberrant H3K79 Methylation by DOT1LCancer Cell, 2011
- Multiple Interactions Recruit MLL1 and MLL1 Fusion Proteins to the HOXA9 Locus in LeukemogenesisMolecular Cell, 2010
- The PAF Complex Synergizes with MLL Fusion Proteins at HOX Loci to Promote LeukemogenesisCancer Cell, 2010
- AFF4, a Component of the ELL/P-TEFb Elongation Complex and a Shared Subunit of MLL Chimeras, Can Link Transcription Elongation to LeukemiaMolecular Cell, 2010
- A Higher-Order Complex Containing AF4 and ENL Family Proteins with P-TEFb Facilitates Oncogenic and Physiologic MLL-Dependent TranscriptionCancer Cell, 2010
- H3K79 Methylation Profiles Define Murine and Human MLL-AF4 LeukemiasCancer Cell, 2008
- The mixed-lineage leukemia fusion partner AF4 stimulates RNA polymerase II transcriptional elongation and mediates coordinated chromatin remodelingHuman Molecular Genetics, 2006